Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study

Fabrizio Stocchi, Olivier Rascol, Karl Kieburtz, Werner Poewe, Joseph Jankovic, Eduardo Tolosa, Paulo Barone, Anthony E. Lang, C. Warren Olanow

Research output: Contribution to journalArticle

Abstract

Objective: L-dopa is the most widely used and most effective therapy for Parkinson disease (PD), but chronic treatment is associated with motor complications in the majority of patients. It has been hypothesized that providing more continuous delivery of L-dopa to the brain would reduce the risk of motor complications, and that this might be accomplished by combining L-dopa with entacapone, an inhibitor of catechol-O-methyltransferase, to extend its elimination half-life. Methods: We performed a prospective 134-week double-blind trial comparing the risk of developing dyskinesia in 747 PD patients randomized to initiate L-dopa therapy with L-dopa/carbidopa (LC) or L-dopa/carbidopa/ entacapone (LCE), administered 4x daily at 3.5-hour intervals. The primary endpoint was time to onset of dyskinesia. Results: In comparison to LC, patients receiving LCE had a shorter time to onset of dyskinesia (hazard ratio, 1.29; p = 0.04) and increased frequency at week 134 (42% vs 32%; p = 0.02). These effects were more pronounced in patients receiving dopamine agonists at baseline. Time to wearing off and motor scores were not significantly different, but trended in favor of LCE treatment. Patients in the LCE group received greater L-dopa dose equivalents than LC-treated patients (p <0.001). Interpretation: Initiating L-dopa therapy with LCE failed to delay the time of onset or reduce the frequency of dyskinesia compared to LC. In fact, LCE was associated with a shorter time to onset and increased frequency of dyskinesia compared to LC. These results may re.ect that the treatment protocol employed did not provide continuous L-dopa availability and the higher L-dopa dose equivalents in the LCE group.

Original languageEnglish
Pages (from-to)18-27
Number of pages10
JournalAnnals of Neurology
Volume68
Issue number1
DOIs
Publication statusPublished - Jul 2010

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study'. Together they form a unique fingerprint.

  • Cite this

    Stocchi, F., Rascol, O., Kieburtz, K., Poewe, W., Jankovic, J., Tolosa, E., Barone, P., Lang, A. E., & Olanow, C. W. (2010). Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study. Annals of Neurology, 68(1), 18-27. https://doi.org/10.1002/ana.22060